Rallybio Corp

RLYB Nasdaq SEC CIK 1739410
Follow Rallybio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$2.7M −117% vs same quarter last year
EPS, diluted −$0.48 −116.9% vs same quarter last year
Operating cash flow −$2.3M +65.3% vs same quarter last year
Revenue by quarter
$38K
$212K
$212K
$212K
$222K
$212K
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$9M
FY24−$57.8M
FY23−$74.6M
FY22−$66.7M
FY21−$47M
FY20−$26.4M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$49.3M
FY23−$60.3M
FY22−$57.3M
FY21−$45.9M
FY20−$22.2M
FY19-